EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
A Fanouriakis, M Kostopoulou, J Andersen… - Annals of the …, 2024 - ard.bmj.com
Objectives To update the EULAR recommendations for the management of systemic lupus
erythematosus (SLE) based on emerging new evidence. Methods An international Task …
erythematosus (SLE) based on emerging new evidence. Methods An international Task …
Is it safe to withdraw low-dose glucocorticoids in SLE patients in remission?
A Mathian, L Arnaud, G Ruiz-Irastorza - Autoimmunity Reviews, 2024 - Elsevier
Glucocorticoids (GCs) remain a cornerstone of the treatment of Systemic Lupus
Erythematosus (SLE). Numerous studies have emphasized the risk of damage accrual in …
Erythematosus (SLE). Numerous studies have emphasized the risk of damage accrual in …
Systemic lupus erythematosus and glucocorticoids: A never-ending story?
D Paredes-Ruiz, G Ruiz-Irastorza, Z Amoura - Best Practice & Research …, 2023 - Elsevier
Glucocorticoids (GCs) continue to be essential agents for the management of systemic lupus
erythematosus, since there are no other drugs able to active remission of active disease so …
erythematosus, since there are no other drugs able to active remission of active disease so …
Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with …
Background Targets of treatment for systemic lupus erythematosus (SLE) include the Lupus
Low Disease Activity State (LLDAS), remission, and complete remission. Whether treatment …
Low Disease Activity State (LLDAS), remission, and complete remission. Whether treatment …
Glucocorticoid tapering and associated outcome in patients with newly diagnosed systemic lupus erythematosus: the real-world GULP prospective observational study
A Floris, E Chessa, GD Sebastiani, I Prevete… - RMD open, 2022 - rmdopen.bmj.com
Objective A subanalysis of the multicentre Early Lupus inception cohort was performed to
investigate the real-world Glucocorticoids (GCs) Use in newly diagnosed systemic lupus …
investigate the real-world Glucocorticoids (GCs) Use in newly diagnosed systemic lupus …
[HTML][HTML] Современная парадигма применения глюкокортикостероидов для лечения иммуновоспалительных заболеваний почек
НМ Буланов, ИН Бобкова, СВ Моисеев - Терапевтический архив, 2023 - cyberleninka.ru
С начала 1950-х годов глюкокортикостероиды (ГКС) остаются одним из основных
компонентов терапии иммуновоспалительных заболеваний почек. Однако …
компонентов терапии иммуновоспалительных заболеваний почек. Однако …
[HTML][HTML] The dichotomy of glucocorticosteroid treatment in immune-inflammatory rheumatic diseases: An evidence-based perspective and insights from clinical …
E Hysa, T Vojinovic, E Gotelli, E Alessandri… - …, 2023 - ncbi.nlm.nih.gov
Objectives Glucocorticosteroids (GCs) are the most used anti-inflammatory and
immunosuppressive drugs due to their effectiveness in managing pain and disease …
immunosuppressive drugs due to their effectiveness in managing pain and disease …
Predictors of flare in SLE patients fulfilling lupus low disease activity state: a cohort study of 292 patients with 36-month follow-up
RN Cunha, L Saraiva, D Jesus, A Doria… - …, 2023 - academic.oup.com
Objectives The treatment target in SLE should be maintained stable by preventing flares.
The objectives were to identify predictors of flare in patients attaining lupus low disease …
The objectives were to identify predictors of flare in patients attaining lupus low disease …
[HTML][HTML] Weaning maintenance therapy in lupus nephritis: for whom, when, and how?
N Jourde-Chiche, M Bobot, S Burtey, L Chiche… - Kidney International …, 2023 - Elsevier
Lupus nephritis (LN) is one of the main determinants of the severity of systemic lupus
erythematosus (SLE). LN flares can lead to organ damage with chronic kidney disease …
erythematosus (SLE). LN flares can lead to organ damage with chronic kidney disease …
Balancing risks and benefits in the use of hydroxychloroquine and glucocorticoids in systemic lupus erythematosus
D Paredes-Ruiz, D Martin-Iglesias… - Expert Review of …, 2024 - Taylor & Francis
Introduction Hydroxychloroquine (HCQ) and glucocorticoids (GCs) constitute the oldest and
more used drugs in the treatment of systemic lupus erythematosus (SLE). Despite this long …
more used drugs in the treatment of systemic lupus erythematosus (SLE). Despite this long …